A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI

Hudson Biotech · ClinicalTrials.gov registration

The first randomised controlled trial of BPC 157 for a musculoskeletal injury. Co-primary endpoints are time to unrestricted sport at 8 weeks and change in MRI-assessed injury volume at day 14 under blinded central radiology review. Registry checked 2026-08-15: first posted 2026-02-27, actual start 2026-02-02, status recruiting, estimated primary completion 2027-02-14, no results posted.

Population

Adults with an acute MRI-confirmed grade II hamstring strain, sites in China

Intervention

Subcutaneous BPC 157 once daily for 14 days alongside standardised rehabilitation

Comparator

Matched placebo injection, 1:1, quadruple-blind

Limitations

Registration only — no data exist yet. Industry sponsor, single country, and a 14-day dosing window against an 8-week functional endpoint.